Showing 4721-4730 of 7765 results for "".
- New PSA From American Academy of Dermatology Highlights Dangers of Tanninghttps://practicaldermatology.com/news/new-psa-from-american-academy-of-dermatology-highlights-dangers-of-tanning/2457753/As Memorial Day signals the unofficial start of summer, many teen girls will be eager to get out of school and spend time outside— and some may want to get a tan. But a new public service advertisement from the American Academy of Dermatology encourages those who are thinking of tanning to
- FDA Approves Lilly's Taltz for Label Update to Treat Psoriasis Involving the Genital Areahttps://practicaldermatology.com/news/fda-approves-lillys-taltz-for-label-update-to-treat-psoriasis-involving-the-genital-area/2457755/The FDA has approved a label update for Taltz (ixekizumab) injection 80 mg/mL to include data in psoriasis involving the genital area. Eli Lilly and Company's Taltz is the first treatment FDA approved for moderate-to-severe plaque psoriasis that includes such data in its label. Taltz was
- EWG: Two-Thirds of Sunscreen Products Offer Poor Protection or Have Worrisome Ingredientshttps://practicaldermatology.com/news/ewg-two-thirds-of-sunscreen-products-offer-poor-protection-or-have-worrisome-ingredients/2457756/The Environmental Working Group (EWG) released its 12th annual Guide to Sunscreens, rating the safety and efficacy of more than 1,000 sunscreens, moisturizers and lip balms that advertise sun protection, and found
- Biotin Supplements Caused Misleading Test Results, Almost Led to an Unnecessary Procedurehttps://practicaldermatology.com/news/biotin-supplements-caused-misleading-test-results-almost-led-to-an-unnecessary-procedure/2457758/A new case report in the Journal of the Endocrine Society documents how a patient's use of a biotin supplement, caused her to have clinically misleading test results, whic
- ASDS: Skin Cancer Treatment Ranks as Most-Performed Procedure of 2017https://practicaldermatology.com/news/asds-skin-cancer-treatment-ranks-as-most-performed-procedure-of-2017/2457761/The American Society for Dermatologic Surgery (ASDS) members performed nearly 12 million medically necessary and cosmetic procedures in 2017 – over 10 percent more than 2016 and doubling since 2012. For the sixth year in a row, the 2017 ASDS Survey on Dermatologic Procedures reveale
- Teledermoscopy Speeds Time to Case Resolution. In Australiahttps://practicaldermatology.com/news/teledermoscopy-speeds-time-to-case-resolution-in-australia/2457768/Teledermatology for skin cancer referral and triage would add to the costs of care but would result in more rapid clinical resolution&m
- Sciton Announces New Leadership Teamhttps://practicaldermatology.com/news/sciton-announces-new-leadership-team/2457777/Sciton has an all new leadership team. The new Sciton leaders are: Aaron Burton, Chief Operating Officer Todd Sternbach, Vice President of Strategic Sales Initiatives David Percival, Vice President / General Manager of Sciton International Lacee Jacobson Na
- Study Seeks to Harness the Power of Probiotics to Treat Eczemahttps://practicaldermatology.com/news/study-seeks-to-harness-the-power-of-probiotics-to-treat-eczema/2457778/A new clinical trial is investigating whether beneficial bacteria can help treat eczema by restoring the natural microbial balance of healthy skin. "There are over 1,000 species of bacteria that all live in balance on healthy skin, some that even produce natural antibiotics. However,
- Tutublue Launches Men's Line of Sunsafe Activewearhttps://practicaldermatology.com/news/tutu-blue-launches-mens-line-of-sunsafe-activewear/2457780/Tutublue, the sun-protective activewear brand, is unveiling a line of men's rash guards and full suits for Summer 2018. Tutublue, designed by California actress and entrepreneur
- FDA Approves Tafinlar + Mekinist for Adjuvant Treatment of BRAF V600-Mutant Melanomahttps://practicaldermatology.com/news/fda-approves-tafinlar-mekinist-for-adjuvant-treatment-of-braf-v600-mutant-melanoma/2457786/The FDA has approved Novartis' Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. The FDA